Trial Profile
An Open-label Clinical Trial to Assess the Pharmacokinetics and Safety of Miltefosine Allometric Dose for the Treatment of Children With Primary Visceral Leishmaniasis in Eastern Africa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2020
Price :
$35
*
At a glance
- Drugs Miltefosine (Primary)
- Indications Visceral leishmaniasis
- Focus Adverse reactions; Pharmacokinetics
- 11 Aug 2020 Results (n=51) of pooled data analysis from two studies (NCT01067443 & NCT02431143) assessing non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients, published in the Journal of Antimicrobial Chemotherapy.
- 10 Oct 2016 Status changed from active, no longer recruiting to completed.
- 29 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.